The FDA has approved the NovoTAL system through a premarket approval supplement. The NovoTAL system allows certified physicians to use the individual MRI data of recurrent glioblastoma multiforme patients to optimize the field distribution and intensity of tumor-treating therapy.
The Sacramento Bee